The aim of the study is to determine the percentage of immigrants who have a lab result related to HIV, VHC, VHB, Chagas disease and intestinal parasites in the first three months after the first visit, according geographical area.
Study Design & Population Method of Assessment Index period: 1st Jan 2013 – 31st Dec 2013 Study Population: Patients diagnosed with MI* and/or PAD* Index Date: Diagnosis of MI or PAD recorded during the index period Inclusion Criteria (MI patients): At least 12 months of history prior to index date (=diagnosis of 1st MI) and 12 months of follow-up post index date Inclusion Criteria (PAD patients): At least 12 months of history prior to index date (=diagnosis of 1st PAD) and 12 months of follow-up post index date Comments/Limitations For patients with both MI and PAD conditions patients will be counted in both groups Date of first MI or PAD diagnosis recorded in the EMR data by the physician during the index period (Note: this may not be the date of the acute event)
The IMI ADVANCE specific objectives guiding this POC for pertussis are: 1. Establish the feasibility of continuously updating the information on the B/R of a vaccine from the first day after a vaccine is marketed 2. Assess IMI ADVANCE platform for data availability on a routinely used vaccine in established vaccination programs covering different populations, and different schedules across countries. 3. To test and assess the level of collaboration between different stakeholders in collecting evidence and integrating evidence on the benefits and risks of vaccines 4. To assess the methods for evidence generation on safety, effectiveness, preferences and vaccination coverage using a near real-time scenario. 5. To evaluate the acceptability of the results by stakeholders for decision making on B/R.
